Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.
JHEP Rep
; 2(5): 100138, 2020 Oct.
Article
en En
| MEDLINE
| ID: mdl-32817930
ALT, alanine aminotransferase; AST, aspartate transaminase; ASV, asunaprevir; BCV, beclabuvir; CT, computed tomography; DAA, direct-acting antiviral; DCV, daclatasvir; Direct acting antiviral; EBR, elbasvir; FIB-4, Fibrosis-4; GLE, glecaprevir; GZR, grazoprevir; Hepatitis C virus; IFN, interferon; LDV, ledipasvir; MRI, magnetic resonance imaging; OBV, ombitasvir; OR, odds ratio; P32del; PI, protease inhibitor; PIB, pibrentasvir; PTV/r, paritaprevir/ritonavir; RAS, resistance-associated substitutions; RBV, ribavirin; Resistance-associated substitution; SOF, sofosbuvir; SVR, sustained virological response; VEL, velpatasvir
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
JHEP Rep
Año:
2020
Tipo del documento:
Article
País de afiliación:
Japón